MOSCOW (Sputnik) – UK-Swedish pharmaceutical firm AstraZeneca has offered its stake in the US Moderna firm for roughly $1.2 billion after Moderna’s shares skyrocketed following the corporate’s breakthrough in the worldwide market of vaccines towards the coronavirus, The Times reported on Monday.
According to the information outlet, following the deal, AstraZeneca removed a 7.7 % stake in Moderna that had earlier made it the biggest investor in the US-based firm.
The Times added that the deal would enable AstraZeneca to enhance its monetary place amid the pharmaceutical large’s plans to amass the US-based Alexion firm for $39 million.
Moderna’s inventory soared in November after the corporate introduced that its vaccine’s efficacy stood at 94.5 %. The optimistic dynamics continued when the US Food and Drug Administration in December accepted emergency use of the Moderna COVID-19 vaccine. This step was adopted by the European Union’s and the United Kingdom’s selections to authorize the usage of the vaccine. On 11 February, Moderna stated that it could ship 200 million doses of its vaccine to the US by May 2021, including that the corporate has signed agreements with numerous international locations on the provision of over 641 million doses.